{
  "url": "https://www.defenseworld.net/2025/04/09/cellectis-nasdaqclls-rating-increased-to-buy-at-stocknews-com.html",
  "title": "Cellectis (NASDAQ:CLLS) Rating Increased to Buy at StockNews.com - Defense World",
  "date_of_publish": "2025-04-09T06:37:00+00:00",
  "author": "Defense World Staff",
  "site_name": "Defense World",
  "tags": [
    "NASDAQ:CLLS",
    "Cellectis,NASDAQ:CLLS,CLLS,Medical,Upgrade,StockNews.com"
  ],
  "content": "Cellectis (NASDAQ:CLLS) Rating Increased to Buy at StockNews.com Posted by on Apr 9th, 2025 Get Cellectis alerts: Cellectis Trading Up 5.0 % Shares of opened at $1.22 on Wednesday. The business has a 50-day moving average price of $1.37 and a 200-day moving average price of $1.68. Cellectis has a twelve month low of $1.10 and a twelve month high of $3.38. The firm has a market cap of $67.70 million, a price-to-earnings ratio of -0.94 and a beta of 3.22. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis ( – ) last released its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.06 by ($0.22). The business had revenue of $33.22 million for the quarter, compared to the consensus estimate of $5.90 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. Equities research analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year. Institutional Investors Weigh In On Cellectis Several hedge funds and other institutional investors have recently made changes to their positions in the company. B Group Inc. purchased a new stake in shares of Cellectis during the fourth quarter valued at $5,547,000. Millennium Management LLC bought a new stake in Cellectis during the fourth quarter valued at about $962,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 12,500 shares in the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock. About Cellectis ( ) Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. Featured Stories Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with ."
}